loading page

Clinical and Echocardiographic Characteristics After Six Months of Sacubitril Valsartan in Chagas Heart Disease.
  • +6
  • Clara Figueiredo,
  • Rodrigo de Melo,
  • Taina Viana,
  • Aline Queiroz de Jesus,
  • Tainara da Silva,
  • Vitor da Silva,
  • William de Carvalho,
  • Daniela da Silva,
  • Luiz Carlos Passos
Clara Figueiredo
Universidade Federal da Bahia

Corresponding Author:clarasfigueiredo@gmail.com

Author Profile
Rodrigo de Melo
Universidade Federal da Bahia
Author Profile
Taina Viana
Universidade Federal da Bahia
Author Profile
Aline Queiroz de Jesus
Universidade Federal da Bahia
Author Profile
Tainara da Silva
Universidade Federal da Bahia
Author Profile
Vitor da Silva
Universidade Federal da Bahia
Author Profile
William de Carvalho
Universidade Federal da Bahia
Author Profile
Daniela da Silva
Universidade Federal da Bahia
Author Profile
Luiz Carlos Passos
Universidade Federal da Bahia
Author Profile

Abstract

Chagas cardiomyopathy is the most prevalent non-ischemic cardiomyopathy in Latin America, with high morbidity and mortality even today. Treatment of these patients is based on the use of medications for heart failure. This study evaluated a cohort of patients with Chagas heart disease who used sacubitril valsartan at a referral hospital for the disease in Brazil. After six months, there was a symptomatic improvement in these individuals assessed by the NYHA classification, with a 44.3% reduction in the absolute number of patients classified as III-IV in the period (p 0.035), but without changes in the parameters on the echocardiogram for reverse ventricular remodeling and still high mortality rate and hospitalization. These results emphasize the importance of studying the use of sacubitril valsartan in chagas heart disease to better describe its effectiveness taking into account the peculiarities of these individuals.
20 Apr 2021Submitted to British Journal of Clinical Pharmacology
21 Apr 2021Submission Checks Completed
21 Apr 2021Assigned to Editor
12 May 2021Reviewer(s) Assigned
15 Jun 2021Review(s) Completed, Editorial Evaluation Pending
15 Jun 2021Editorial Decision: Revise Minor
29 Jun 20211st Revision Received
30 Jun 2021Submission Checks Completed
30 Jun 2021Assigned to Editor
30 Jun 2021Review(s) Completed, Editorial Evaluation Pending
30 Jun 2021Editorial Decision: Accept